arisugacin and Alzheimer-Disease

A computation docking study of the highly potent, non-nitrogen containing, acetylcholinesterase inhibitor (+)-arisugacin A is presented. The model suggests that (+)-arisugacin A is a dual binding site covalent inhibitor of AChE. These findings are examined in the context of Alzheimer's disease-modifying therapeutic design. (+)-Arisugacin A's revealed mode of action is unique, and may serve as a basis for the development of AD therapeutics capable of treating the symptomatic aspects of AD, while being neuroprotective with long term efficacy.

Topics: Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Computer Simulation; Inhibitory Concentration 50; Models, Biological; Models, Molecular; Molecular Structure; Pyrans